ACB
Price
$5.49
Change
+$0.27 (+5.17%)
Updated
May 22 closing price
Capitalization
238.86M
27 days until earnings call
INCR
Price
$1.58
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
123.5M
87 days until earnings call
Interact to see
Advertisement

ACB vs INCR

Header iconACB vs INCR Comparison
Open Charts ACB vs INCRBanner chart's image
Aurora Cannabis
Price$5.49
Change+$0.27 (+5.17%)
Volume$827.64K
Capitalization238.86M
Intercure
Price$1.58
Change-$0.00 (-0.00%)
Volume$245
Capitalization123.5M
ACB vs INCR Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. INCR commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and INCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ACB: $5.49 vs. INCR: $1.58)
Brand notoriety: ACB: Notable vs. INCR: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 79% vs. INCR: 2%
Market capitalization -- ACB: $238.86M vs. INCR: $123.5M
ACB [@Pharmaceuticals: Other] is valued at $238.86M. INCR’s [@Pharmaceuticals: Other] market capitalization is $123.5M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • INCR’s FA Score: 1 green, 4 red.
According to our system of comparison, INCR is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while INCR’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 4 bearish.
  • INCR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ACB and INCR are a good buy in the short-term.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +10.69% price change this week, while INCR (@Pharmaceuticals: Other) price change was +4.46% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.08%. For the same industry, the average monthly price growth was +10.49%, and the average quarterly price growth was +31.12%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

INCR is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.08% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($239M) has a higher market cap than INCR($124M). ACB YTD gains are higher at: 29.176 vs. INCR (-0.792). INCR has higher annual earnings (EBITDA): 25.8M vs. ACB (-1.64B). ACB has more cash in the bank: 149M vs. INCR (103M). ACB has less debt than INCR: ACB (103M) vs INCR (163M). INCR has higher revenues than ACB: INCR (415M) vs ACB (212M).
ACBINCRACB / INCR
Capitalization239M124M193%
EBITDA-1.64B25.8M-6,345%
Gain YTD29.176-0.792-3,682%
P/E RatioN/A22.52-
Revenue212M415M51%
Total Cash149M103M145%
Total Debt103M163M63%
FUNDAMENTALS RATINGS
ACB vs INCR: Fundamental Ratings
ACB
INCR
OUTLOOK RATING
1..100
205
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8994
PRICE GROWTH RATING
1..100
4752
P/E GROWTH RATING
1..100
684
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (57) in the Servicestothe Health Industry industry is in the same range as ACB (58) in the Pharmaceuticals Other industry. This means that INCR’s stock grew similarly to ACB’s over the last 12 months.

INCR's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that INCR’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that ACB’s stock grew similarly to INCR’s over the last 12 months.

ACB's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as INCR (52) in the Servicestothe Health Industry industry. This means that ACB’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is somewhat better than the same rating for ACB (68) in the Pharmaceuticals Other industry. This means that INCR’s stock grew somewhat faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBINCR
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOPX31.60N/A
N/A
Patient Opportunity C
VSOYX42.21N/A
N/A
Victory Sycamore Small Company Opp Y
AEMOX29.27N/A
N/A
Virtus EM Opps R6
NWXQX15.76N/A
N/A
Nationwide Mid Cap Market Idx Instl Svc
LHCCX16.79N/A
N/A
Lord Abbett Health Care C

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+5.17%
CGC - ACB
79%
Closely correlated
N/A
SNDL - ACB
65%
Loosely correlated
N/A
OGI - ACB
61%
Loosely correlated
+2.24%
CRON - ACB
57%
Loosely correlated
N/A
TLRY - ACB
57%
Loosely correlated
+3.26%
More

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and TLRY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and TLRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
N/A
TLRY - INCR
29%
Poorly correlated
+3.26%
KMDA - INCR
26%
Poorly correlated
N/A
SNDL - INCR
25%
Poorly correlated
N/A
ACB - INCR
24%
Poorly correlated
+5.17%
OGI - INCR
24%
Poorly correlated
+2.24%
More